An Exploratory Study on Anti-tumour Activity of Orally Administered RO4929097, a Gamma-secretase Inhibitor, as a Single Agent in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer (NSCLC).
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumour blood flow and tumour metabolic response rate
PET and CT assessments on day 4 (cycle 1) and day 16 (cycles 1 and 2)
Netherlands: Dutch Health Care Inspectorate